Literature DB >> 27153747

Burden of neurological conditions in Canada.

J Gaskin1, J Gomes2, S Darshan3, D Krewski4.   

Abstract

Neurological conditions are among the leading causes of disability in the Canadian population and are associated with a large public health burden. An increase in life expectancy and a declining birth rate has resulted in an aging Canadian population, and the proportion of age-adjusted mortality due to non-communicable diseases has been steadily increasing. These conditions are frequently associated with chronic disability and an increasing burden of care for patients, their families and caregivers. The National Population Health Study of Neurological Conditions (NPHSNC) aims to improve knowledge about neurological conditions and their impacts on individuals, their families, caregivers and health care system. The Systematic Review of Determinants of Neurological Conditions, a specific objective within the NPHSNC, is a compendium of systematic reviews on risk factors affecting onset and progression of the following 14 priority neurological conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), brain tumours (BT), cerebral palsy (CP), dystonia, epilepsy, Huntington's disease (HD), hydrocephalus, multiple sclerosis (MS), muscular dystrophies (MD), neurotrauma, Parkinson's disease (PD), spina bifida (SB), and Tourette's syndrome (TS). The burden of neurological disease is expected to increase as the population ages, and this trend is presented in greater detail for Alzheimer's and Parkinson's disease because the incidence of these two common neurological diseases increases significantly with age over 65 years. This article provides an overview of burden of neurological diseases in Canada to set the stage for the in-depth systematic reviews of the 14 priority neurological conditions presented in subsequent articles in this issue.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Disease burden; Incidence; Neurological conditions; Onset; Prevalence; Progression; Risk factors; Systematic review

Mesh:

Year:  2016        PMID: 27153747     DOI: 10.1016/j.neuro.2016.05.001

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  6 in total

1.  Neurosciences, Rehabilitation and Vision Strategic Clinical Network: Improving how Albertans see, think and live.

Authors:  Nicole McKenzie; Petra O'Connell; Chester Ho
Journal:  CMAJ       Date:  2019-12-04       Impact factor: 8.262

2.  Streamlining the management of Parkinson disease in Canada.

Authors:  Veronica Bruno; Maria Eliza Thomaz de Freitas
Journal:  CMAJ       Date:  2019-09-09       Impact factor: 8.262

3.  Canadian healthcare capacity gaps for disease-modifying treatment in Huntington's disease: a survey of current practice and modelling of future needs.

Authors:  Angèle Bénard; Sylvain Chouinard; Blair R Leavitt; Nathalie Budd; Jennifer W Wu; Kerrie Schoffer
Journal:  BMJ Open       Date:  2022-06-01       Impact factor: 3.006

4.  Survey-based identification of design requirements and constraints for a wearable tremor suppression device.

Authors:  Yue Zhou; Devin Box; Kenneth G Hardy; Mary E Jenkins; Jayne Garland; Michael D Naish; Ana Luisa Trejos
Journal:  J Rehabil Assist Technol Eng       Date:  2022-05-07

5.  Comparing Activity and Participation between Acquired Brain Injury and Spinal-Cord Injury in Community-Dwelling People with Severe Disability Using WHODAS 2.0.

Authors:  Seo Yeon Yoon; Ja-Ho Leigh; Jieun Lee; Wan Ho Kim
Journal:  Int J Environ Res Public Health       Date:  2020-04-27       Impact factor: 3.390

6.  Longitudinal Assessment of Behaviour and Associated Bio-Markers Following Chronic Consumption of β-Sitosterol β-D-Glucoside in Rats: A Putative Model of Parkinson's Disease.

Authors:  Logan J Bigelow; Melissa A Perry; Sarah L Ogilvie; R Andrew Tasker
Journal:  Front Neurosci       Date:  2022-02-24       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.